Merck & Co., Inc. Derivative, Collateral, Right to Reclaim Securities
Merck & Co., Inc. (MRK) had Derivative, Collateral, Right to Reclaim Securities of $19.00 million as of 2022-12-31, per its 10-K filed 2024-02-26.
Discontinued › Notes › Offsetting › Offsetting Derivative Liabilities › Derivative Liability, Subject to Master Netting Arrangement, after Offset and Deduction
us-gaap:DerivativeCollateralRightToReclaimSecurities · last filed 2024-02-26
- 2022-12-31: Derivative, Collateral, Right to Reclaim Securities $19.00M.
| Period end | Derivative, Collateral, Right to Reclaim Securities |
|---|---|
| 2022-12-31 | $19.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |